D09 - The Great Debate: Going with the Flo or Turning the Tides in T2D Management

Sunday, August 10, 2025

10:00 AM – 10:45 AM MT

CE/CME Hours: .75 CE

Pharmacology Hours: .75 CE

Primary Presenter(s)

Katelyn O'Brien, PharmD, BCPS, CDCES, BC-ADM (she/her/hers)

Clinical Pharmacy Specialist
Boston Medical Center
Dorchester, Massachusetts

Disclosure(s): Bayer Pharmaceuticals: Consultant / Advisory Board (Terminated, May 6, 2023); Eli Lilly: Consultant / Advisory Board (Terminated, October 18, 2024); Sanofi: Consultant / Advisory Board (Terminated, September 27, 2024)

Co-Presenter(s)

KB

Kyle Bertam, PharmD, BCACP, CDCES

Clinical Pharmacy Specialist
Boston Medical Center
Boston, Massachusetts

Disclosure(s): No financial relationships to disclose

For many years metformin was the first line treatment for managing T2D. However, in recent years the ADA Standards of Care have adopted a cardiorenal metabolic approach to medication selection. With many options in this new approach, it can be difficult to choose which medication to initiate. This debate-style presentation will analyze the evidence to support use of SGLT2i or incretin therapy using patient-centric approaches. The knowledge gained in the session will empower the DCES to avoid clinical inertia, educate patients and providers, and recommend guideline-concordant therapies to reduce cardiovascular, renal, and metabolic complications associated with diabetes.

Disclosure(s):

Katelyn O'Brien, PharmD, BCPS, CDCES, BC-ADM: Bayer Pharmaceuticals: Consultant / Advisory Board (Terminated, May 6, 2023); Eli Lilly: Consultant / Advisory Board (Terminated, October 18, 2024); Sanofi: Consultant / Advisory Board (Terminated, September 27, 2024)

Kyle Bertam, PharmD, BCACP, CDCES: No financial relationships to disclose